ABT-102

ABT-102 is a potent and highly selective Vanilloid Receptor (TRPV1) receptor antagonist. ABT-102 potently and reversibly increases heat pain thresholds and reduced painfulness of suprathreshold oral/cutaneous heat. ABT-102 reduces nociceptive responses of animals in models of inflammatory, bone cancer, postoperative, and osteoarthritic pain[1][2].

Product Specifications

CAS Number

[808756-71-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

TRP Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/abt-102.html

Concentration

10mM

Purity

98.50

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=CC2=C1C=NN2)N[C@@H]3CCC4=C3C=CC(C(C)(C)C)=C4

Molecular Formula

C21H24N4O

Molecular Weight

348.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Lukin K, et al. Development of a Large Scale Asymmetric Synthesis of Vanilloid Receptor (TRPV1) Antagonist ABT-102. Organic Process Research & Development, 2007, 11 (3) :578-584.|[2]Rowbotham MC, et al. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain. 2011 May;152 (5) :1192-1200.